Coverage of "Retatrutide" on cryptobo.eu: the stories and the context behind them.
Eli Lilly shares rose 2% after fresh clinical data on retatrutide impressed investors, though the FDA filing has been pushed back to Q1 2027. Analysts still project up to $3.8 billion in annual revenue from the drug by 2030.
